Search

Be part of the EHA community

How you can take an active role and help drive EHA's direction. As a membership organization, EHA is dependent on the dedication of its board and committee members.

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Meeting program

Thursday, October 12*All times are in EET.

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.